Making Tomorrow’s
Cancer Treatment Better

We are Isofol

Isofol is a publicly listed biotech company developing the drug candidate arfolitixorin to enhance the efficacy of standard treatment for patients with severe forms of cancer.

Our goal is s to have a central impact on tomorrow’s cancer treatment, giving more patients the opportunity to respond better to their treatment, improve  their prognosis, and gain more time with life.

Isofol’s share is listed on Nasdaq Stockholm.